The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects.
Drug Discov Today
; 26(10): 2269-2281, 2021 10.
Article
in English
| MEDLINE | ID: covidwho-1198694
ABSTRACT
Coronavirus 2019 (COVID-19) has caused significant disruption to the cell and gene therapy (CGT) industry, which has historically faced substantial complexities in supply of materials, and manufacturing and logistics processes. As decision-makers shifted their priorities to COVID-19-related issues, the challenges in market authorisation, and price and reimbursement of CGTs were amplified. Nevertheless, it is encouraging to see that some CGT developers are adapting their efforts toward the development of promising COVID-19-related therapeutics and vaccines. Manufacturing resilience, digitalisation, telemedicine, value-based pricing, and innovative payment mechanisms will be increasingly harnessed to ensure that market access of CGTs is not severely disrupted.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Genetic Therapy
/
Health Care Sector
/
Cell- and Tissue-Based Therapy
/
COVID-19
Type of study:
Experimental Studies
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Drug Discov Today
Journal subject:
Pharmacology
/
Drug Therapy
Year:
2021
Document Type:
Article
Affiliation country:
J.drudis.2021.04.020
Similar
MEDLINE
...
LILACS
LIS